Allogene Therapeutics, Inc. (ALLO)

Every figure this model derived for ALLO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 402,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 332,604,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 340,000,000 AssetsCurrent 2026-06-30
current liabilities 31,727,000 LiabilitiesCurrent 2026-06-30
equity 436,175,000 StockholdersEquity 2026-06-30
interest expense 1,300,000 InterestExpenseNonoperating 2026-06-30
ocf -102,196,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 37,492,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ALLO on one particular measure came for.

RatioValue
current ratio10.72
current ratio reported10.72
deferred revenue growth-68.5
dilution pct13.26
interest cover-138.71
revenue growth-100.0
revenue growth per share-100.0
roic-137.54

What to be careful about

What this model itself distrusts about ALLO's figures. Written by the derivation as it ran, not added afterwards.